Lonza and Onava Formed Biologics Discovery Partnership
The collaboration leverages AI-native drug discovery to bridge computational prediction with wet-lab data generation.
Updated on Oct. 10, 2026 in Biotech
Live Poll
Do you trust that using AI for drug discovery will lead to safer medical treatments?
Lonza and Onava have announced a research evaluation agreement focused on AI-enabled biologics discovery. The partnership centers on the application of Lonza's GS Gene Expression System to accelerate development timelines.
Why it matters
By connecting computational modeling with biological validation, this collaboration seeks to shorten the feedback loop in protein engineering. It represents an industry push to move from predictive models to verifiable, AI-native drug design.
The agreement utilizes the GS Gene Expression System, a mammalian cell-based platform for protein production, alongside GS Ori-Go vectors. These tools provide the standardized genetic framework for expressing novel biological candidates identified by Onava's AI models.
The players
Lonza
A Swiss-based multinational manufacturer known for its comprehensive CDMO stack, supplying specialized cell lines and expression systems for the biopharma industry.
Onava
A U.S.-based biotech entity focused on integrating artificial intelligence into the biologics discovery workflow to shorten development cycles.
The details
Onava will utilize the GS Gene Expression System, a production technology for manufacturing therapeutic proteins, to validate outcomes from its AI discovery pipeline. GS Ori-Go vectors — specialized DNA molecules used to deliver and integrate genetic instructions into host cells — are being deployed to streamline the transition from digital prediction to physical biological expression. This integration allows the companies to feed empirical data from cell culture back into computational models, refining future predictions.
Timeline
October 9, 2026: The companies announced the partnership.
The Tech Race
This move marks a tactical shift as legacy manufacturing infrastructure providers like Lonza increasingly adopt AI-native partners to maintain dominance in the biologics supply chain. It follows an industry pattern of integrating computational simulation with high-throughput biological verification.
The collaboration is currently in the research evaluation phase, meaning no products are near clinical application. Its success will be measured by the speed at which Onava can validate AI-generated candidates using Lonza’s production systems in future development cycles.
The takeaway
This agreement highlights the growing necessity of blending AI-driven predictive modeling with standardized manufacturing platforms to reach drug targets faster. Observers should track subsequent progress reports for data on time-to-discovery metrics compared to traditional, non-AI-integrated workflows.
Further reading
For more on the current state of drug design, visit our Biotech section.
Live Poll
Do you trust that using AI for drug discovery will lead to safer medical treatments?
